Literature DB >> 10076708

Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome.

A Tsukadaira1, Y Okubo, K Kitano, S Horie, T Momose, S Takashi, J Suzuki, M Isobe, M Sekiguchi.   

Abstract

There are few reports regarding the measurement of cytokines and surface analysis of eosinophils in Churg-Strauss syndrome (CSS). To examine the pathophysiology of CSS, concentrations of cytokines in serum and bronchoalveolar lavage fluid (BALF), and surface antigens on peripheral blood eosinophils were analyzed in five patients with CSS. Concentrations of cytokines (interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-3 (IL-3), interleukin-5 (IL-5) and granulocyte/macrophage colony stimulating factor (GM-CSF) were measured using ELISA. Surface antigens on eosinophils in peripheral blood were analyzed using flow cytometry. A concentration of interleukin-5 (IL-5) and TNF-alpha in serum was detected in five cases; however IL-1 beta, GM-CSF, and IL-3 were detected in 3 of 5, 2 of 5, and 1 of 5 patients, respectively. In BALF, TNF-alpha and IL-5 were detected in 2 of 3 and 1 of 3 patients, respectively; however, neither IL-1 beta, GM-CSF, nor IL-3 was detected in any. Newly expressed surface antigens such as CD25, CD4, and CD69 were observed on peripheral blood eosinophils in five cases. CD54 and HLA-DR were expressed in 4 of 5 and 3 of 5 patients, respectively. Eosinophils in peripheral blood are activated to various degrees, possibly depending on cytokine stimulation. This eosinophil activation may be related to the clinical stage of CSS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076708     DOI: 10.2500/108854199778681486

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  12 in total

Review 1.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 2.  Cutting edge issues in the Churg-Strauss syndrome.

Authors:  Wojciech Szczeklik; Bogdan Jakieła; Dariusz Adamek; Jacek Musiał
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 3.  Cytokines and adhesion molecules in the pathogenesis of vasculitis.

Authors:  J S Sundy; B F Haynes
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

4.  Etanercept prevents airway hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs.

Authors:  Zhenying Nie; David B Jacoby; Allison D Fryer
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 5.  Advances in the treatments of systemic vasculitides.

Authors:  Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

6.  [Update Churg-Strauss syndrome].

Authors:  F Moosig; B Hellmich
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

Review 7.  Churg-Strauss syndrome: 2005-2008 update.

Authors:  Rafael G Grau
Journal:  Curr Rheumatol Rep       Date:  2008-12       Impact factor: 4.592

Review 8.  Indications for biotherapy in systemic vasculitides.

Authors:  Loïc Guillevin; Christian Pagnoux; Philippe Guilpain; Boris Bienvenu; Valérie Martinez; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

Review 9.  Eosinophils in Autoimmune Diseases.

Authors:  Nicola L Diny; Noel R Rose; Daniela Čiháková
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

10.  Effective intravenous immunoglobulin therapy for Churg-Strauss syndrome (allergic granulomatous angiitis) complicated by neuropathy of the eighth cranial nerve: a case report.

Authors:  Yoshio Ozaki; Akihiro Tanaka; Keiko Shimamoto; Hideki Amuro; Yonsu Son; Tomoki Ito; Shosaku Nomura
Journal:  J Med Case Rep       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.